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ABSTRAK 
KAJIAN RETROSPEKTIF: PENGGUNAAN PLASMA BEKU SEGAR DI 
HOSPITAL SELAYANG 
Latarbelakang. Transfusi plasma beku segar telah meningkat dan menjadi popular 
kebelakangan ini. Ia telah mula digunakan sejak tahun 1920-an dan apabila 
digunakan dengan indikasi yang betul ia dapat menjadi satu rawatan moden yang 
membantu dalam penyembuhan pesakit. Namun transfusi plasma darah juga boleh 
mendatangkan kemudaratan kepada pesakit seperti alergik, TRALI, TACO dan 
jangkitan penyakit berjangkit. Oleh itu, kajian ini dijalankan untuk mengenal pasti 
indikasi yang betul mengikut garis panduan yang telah ditetapkan bagi transfusi 
plasma beku segar. 
Objektif. Menilai indikasi transfusi plasma beku segar samada mengikut garis 
panduan ataupun tidak kepada pesakit yang menerima transfusi darah di Hospital 
Selayang. Garis panduan yang digunakan adalah dari Pusat Darah Negara dan 
College of American Pathologist.  
Kaedah. Kajian retrospektif di kalangan pesakit dewasa yang terlibat di dalam 
transfusi plasma beku segar di Hospital Selayang antara Januari 2016 sehingga 
Disember 2016. Data diambil dari sistem komputer yang dikenali sebagai total 
hospital information system (THIS) borang permintaan darah dan borang reaksi 
transfusi darah. 
Keputusan. Sejumlah 373 pesakit telah disertakan di dalam kajian ini, dan sebanyak 
73.2% keputusan adalah mengikut indikasi manakala 26.8% keputusan tidak 
mengikut indikasi. Jabatan Hepato Pancreator Biliari dan Ortopedik merupakan 
jabatan yang paling banyak melakukan transfusi plasma beku segar tanpa mengikut 
XIII 
 
indikasi. Bacaan INR yang normal pula menunjukkan 3.22 kebarangkalian untuk 
diberikan kepada kumpulan yang tidak mengikut indikasi. Transfusi reaksi yang 
terbanyak adalah alergik dan demam yang tidak disebabkan oleh reaksi hemolisis 
(febrile non haemolytic reaction). 
Kesimpulan. Transfusi plasma beku segar tanpa mengikut indikasi mendedahkan 
pesakit kepada risiko reaksi transfusi dan ia patut dicegah dan dikawal sehabis baik. 
Hasil penemuan di dalam kajian ini diharapkan dapat memberi manfaat kepada para 
doktor di dalam membuat keputusan yang betul ketika transfusi darah diperlukan. 
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ABSTRACT 
USE OF FRESH FROZEN PLASMA AT HOSPITAL SELAYANG: A 
RETROSPECTIVE STUDY 
Background. FFP transfusion has increased in demand over the years and the global 
trending of high FFP usage can be seen in many countries. It has been used since 
1920’s and if appropriately used, it can improve the quality of life. However FFP 
transfusion is not without risk. It may cause adverse transfusion reaction such as 
allergic reaction, TRALI, TACO and transfusion transmitted infections. Thus this 
study was conducted to assess the indication of FFP transfusion against the guideline 
available.  
Objective. To assess the appropriateness of the use of fresh frozen plasma at 
Hospital Selayang against the National Guideline for the rationale use of blood and 
blood products and international guideline by College of American Pathologist. 
Method. A retrospective study among adult patients receiving fresh frozen plasma 
from 1 January 2016 until 31 December 2016 by reviewing total hospital information 
system (THIS), blood order and transfusion reaction forms. The appropriateness of 
requests was assessed against existing guidelines. The percentage of indicated 
diagnosis (appropriate) and not indicated diagnosis (inappropriate) FFP transfusions 
were obtained. 
Result. Total of 373 patients receiving FFP were included in this study. About 
73.2% of the patients were given FFP with indicated diagnosis and is considered 
appropriate while 26.8% was inappropriate. HPB and Orthopaedic are the most 
departments to transfused FFP inappropriately. Those with normal INR were 3.22 
times higher odds of being inappropriate for FFP transfusion compared to those with 
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prolong INR readings. Total of 4.3% patients developed transfusion reaction mainly 
mild allergic and febrile non hemolytic reaction (FNHR). 
Conclusion. Inappropriate transfusion exposes patient to unnecessary adverse event 
and thus should be monitored and prevented by all means. The findings of this study 
are beneficial to justify the role of clinicians in making the right decision in 
transfusion practices. 
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CHAPTER 1 
INTRODUCTION 
1.1 Title 
Use of Fresh Frozen Plasma at Hospital Selayang: A Retrospective Study 
1.2 Overview 
Transfusing blood and blood component has become an essential part of modern 
health care. In appropriate usage, it can improve the quality of life and prevent 
morbidity and mortality (National Blood Centre, 2010). However, blood transfusion 
comes with major problems concerning over safety, cost and availability. Despite 
meticulous process and procedures in place to ensure blood safety, the risk of 
complication still remains. Therefore, it is very important to comply the guidelines. 
All health care professionals who are involved in patient management need to 
comply with transfusion practices, guidelines for appropriate blood use, the 
availability of particular blood products and patient specific blood product needs 
(Shander and Goodnough, 2007). 
 
Blood Transfusion Services (BTS) aim to provide ‘safe and adequate’ blood at 
any time (National Blood Centre, 2016). To achieve this goal, BTS is governed by 
national blood policy and legislative framework to promote uniform implementation 
of standards and consistency in the quality and safety of blood and blood products. 
According to WHO in 2013, 122 out of 179 (68%) of reporting countries all over the 
world had a national blood policy. In Malaysia, ‘Transfusion Practice Guidelines for 
Clinical and Laboratory Personnel’ and ‘Guidelines for the Rational Use of Blood 
and Blood Products’ have been established following relevant requirements of 
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established standards such as MS ISO 15189, current Good Manufacturing Practice 
(GMP) and Good Clinical Practice (GCP). These guidelines served as a 
comprehensive guidance for blood transfusion practices and guidelines for 
appropriate blood used. Despite of having a clearly defined guideline, patients 
continue to received unnecessary transfusion every day (Asif et al., 2013). 
Furthermore, the availability of blood and blood product is also an important 
aspect to be considered. Blood is a limited resource and it is important to rationalize 
and optimize transfusion practice (Roback et al., 2008). According to Dr S. 
Subramaniam (Ministry of Health) in Malay Mail, only 2.2% of Malaysian 
population is a blood donor (Edward, 2015). According to United Nations, the 
current population of Malaysia is 30,906,650 as of November 2016. About 2.2% of 
this current population makes only about 600,000 Malaysians are blood donor. The 
percentage of Malaysian blood donor is low compared to the recommendation by 
WHO which is 3.5%-5% of the population in developing countries.   
Blood is obtained from voluntary, non-remunerated blood donors.  An 
anticoagulant is used enabling them to be stored and transfused to a patient. Two 
collection methods are used; whole blood donation and apheresis donation. Whole 
blood donation is separated into multiple component such as red cell, platelet and 
plasma while apheresis is the collection of a specific blood component by a 
specialized cell separator machine that centrifuges the donor’s whole blood, 
separates and removes the desired component (plasma, platelets, RBCs, or 
granulocytes) and returns all other blood components to the donor (Norfolk, 2013). 
Nowadays, blood can be used more effective if it is processed into components such 
as red cell concentrate, platelet concentrate, plasma, cryoprecipitate and 
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cryosupernatant. By performing blood component processing, the need of more than 
one patient can be meet (WHO, 2017). Since components transfusion is said to be 
more effective, fresh frozen plasma as one of the blood components was chosen to be 
studied. 
Frank Hartman performed the first plasma transfusion to treat the Spanish flu 
in 1918. In the late of 1920’s and 1930’s plasma started to become routinely used in 
hospitals. Within the era, plasma was produced in two forms which were dried and 
frozen and studies showed both were just effective and much easier to store. 
However during World War II, United State army used dried plasma as a blood 
substitute but it was found that manufacturing of dried plasma causes prothrombin 
depletion. Thus, fresh frozen plasma has become a more superior product (Puetz, 
2013).  
Fresh Frozen plasma (FFP) is a plasma product derived from human collected 
via whole blood or apheresis donation. It is prepared by freezing it at -18°C or colder 
within 8 hours of collection and can be stored for a year (Bucur and Hillyer, 2001). 
FP24 is plasma unit that is frozen within 24 hours after collection and is commonly 
practiced in the United State (Eder and Sebok, 2007). FFP is thawed at 30°C to 37°C 
and once thawed the shelf life is 5 days when stored at 1°C to 6°C (Triulzi and 
Yazer, 2010).  The practice of FFP production in Malaysia as stated in Transfusion 
Practice Guideline is described in table 1. 
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Table 1: Definition, criteria, preparation method, storage and shelf life of FFP 
 
 
Component FFP 
Definition A component which contains labile clotting factors and other 
constituents, for transfusion or fractionation. 
Criteria for 
preparation 
Duration of whole blood donation shall not exceed 15 minutes. 
Plasma should be prepared within 24 hours of whole blood 
collection, preferably within 12 hours. 
Preparation Plasma is obtained from whole blood after centrifugation, or by 
plasma apheresis and immediately frozen to achieve complete 
freezing within 1 hour to a core temperature of below minus 
30°C (-30°C). 
Storage 
temperature 
and shelf life 
a. 36 months at or below -25°C (≤-25°C). 
b. 3 months at -18°C to -25°C. 
 
 
 
 The content of FFP include immunoglobulin, albumin, coagulation factors 
and fibrinolytic proteins, ionic solutes and trace elements (Basu and Kulkarni, 2014). 
FFP prepared from whole blood and apheresis donation may differ only in the 
quantity of plasma in the pack. The volume may vary from 180ml to 400ml 
(O'shaughnessy et al., 2004). 
According to John Puetz, the typical amount of FFP used in adults is 2 units, 
with a unit of FFP derived from whole blood donation of a single donor. A unit of 
FFP is about average of  200ml (Puetz, 2013). FFP dose can also be calculated using 
dose of 10-15ml of plasma per kg body weight. However the dose  can exceeded in 
the case of massive bleeding. Hence , FFP dose relies on patient clinical condition, 
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plasma volume and the target increment of coagulation factors in post transfusion 
patient (O'shaughnessy et al., 2004). 
FFP transfusion is not without risk, and certain complications are more likely to 
occur in FFP transfusion compared to other blood components for example 
transfusion related lung injury (TRALI), transfusion associated circulatory overload 
(TACO), allergic or anaphylactic reactions. Other less common complications  are 
transmitted transfusion infection (TTI) such as HIV, HepB, HepC or syphilis, febrile 
non haemolytic transfusion reaction, Red blood cell (RBC) allo-immunization and 
haemolytic transfusion reaction (Pandey and Vyas, 2012). FFP has also been linked 
with transfusion associated graft versus host disease (TAGVHD) and transfusion 
related mortality (Vamvakas and Blajchman, 2009). 
Although transfusion of FFP is associated with multiple adverse effects and risks 
ranging from mild to possible fatal outcome, the global trending of FFP usage has 
increased through years and all around the world. In United States (US), 2.3 million 
units of FFP were transfused in 1991 and increased to 3.9 million in 2001. In  2008, 
4.5 million unit of FFP were transfused which was 11.8% increased from 2006 
(Pandey and Vyas, 2012). In United Kingdom (UK), high trend of FFP usage has 
been observed too. British Safety Hazards of Transfusion (SHOT) annual report from 
2010 to 2015 stated that total of 266,332 units of FFP were transfused in 2013, 
followed by 247,466 in 2014 and 232,902 in 2015 (refer to Table 2). High trend of 
component usage can also be seen in Australia.  According to Australian 
Haemovigilance Report (Data for 2011-2 and 2012-13), the decreasing trend in 
demand of FFP usage was probably because of improving success of appropriate 
usage and reducing wastage (National Blood Authority Advisory Committee, 2015).  
6 
 
Table 2: Units of FFP transfused since 2010 until 2015 reported in Safety of Hazards 
Transfusion (SHOT) annual report in UK 
Year Red Blood 
Cells 
Platelets FFP Cryoprecipitate Totals 
2010 2,180,781 246,962 292,884 120,311 2,840,938 
2011 2,162,137 301,628 288,242 126,170 2,878,177 
2012 2,146,783 311,737 282,721 44,108 2,785,349 
2013 2,043,046 312,140 266,332 43,957 2,665,475 
2014 1,966,866 318,539 247,466 43,156 2,576,027 
2015 1,893,812 310,673 232,902 43,645 2,481,032 
 
Table 3: Units of FFP transfused since 2009 until 2013 in Australian Haemovigilance 
Report (National Blood Authority Australia) 
Year Red 
Blood 
Cells 
Platelets FFP Cryoprecipitate Totals 
2009 to 2010 795,892 128, 495 160,813 64,734 225,547 
2010 to 2011 800,570 134,705 160,537 70,102 230,639 
2011 to 2012 801,295 134,149 159,024 78,099 237,123 
2012 to 2013 763,542 134,576 147,641 85,692 233,333 
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Hospital Selayang received the resources of blood and blood component from 
National Blood Centre (NBC). Table 4 shows the unpublished data of FFP usage in 
Hospital Selayang since 2012 until 2016. Increased demand for FFP could be seen in 
three consecutive years from 6,075 in 2013 to 6,424 in 2014 and 6,881 in 2015. This 
increasing in demand raised a question on appropriateness of FFP transfusion and 
whether the judgement made based on patient benefit or assumption only. It also 
raises our concern on the risks of transfusion reaction including the under reported 
adverse events. 
 
Table 4: Unpublished data Units of FFP transfused in Hospital Selayang since 2012 
until 2016 
Year FFP 
2012 6,416 
2013 6,075 
2014 6,424 
2015 6,881 
2016 6,497 
 
The numbers of cases for FFP related transfusion reaction were 36 cases in 
2015 and 30 cases in 2016. . The most common type of reaction was allergic and 
febrile non haemolytic reaction. Table 5 and 6 summarized transfusion reaction 
(unpublished data) in Hospital Selayang for 2015 and 2016. 
 
 
8 
 
Table 5: Unpublished data type of product involved in transfusion reaction in 
hospital selayang for 2015 and 2016 
Year 
Type of products involved in transfusion reaction (n) 
Whole 
blood 
RBC platelet FFP Cryoprecipitate 
 
2015 
 
2 
 
135 
 
6 
 
36 
 
0 
2016 0 113 4 30 0 
 
Table 6: Unpublished data type of transfusion reaction occur in Hospital Selayang in 
2015 and 2016 
Type of transfusion 
reaction 
2015 2016 
Allergic   85 69 
Anaphylactic 1 0 
Febrile non haemolytic 84 70 
Acute/delayed haemolytic  0 0 
TACO 1 1 
TRALI 0 0 
Bacterial contamination 0 0 
Others 8 7 
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1.3 Literature Review 
1.3.1 Introduction 
FFP is a blood product produce from plasma that is separated from packed 
red cells and platelets after centrifugation of whole blood donation or apheresis 
donation frozen at -30°C within 6 to 8 hours of phlebotomy (Razzak et al., 2014). It 
had been introduced into clinical practice and was initially used as volume 
replacement therapy during World War II by US army. Better understanding of the 
clinical use of FFP has contributed to the change in practice of FFP transfusion 
through time.  Generally, FFP is frequently used to either as prophylaxis before 
invasive procedure or surgery to prevent bleeding or as therapeutic to stop bleeding  
(Stanworth et al., 2007) 
Human plasma has more than 120 proteins that are involved in transportation, 
enzymatic activities and haemostasis. One ml of plasma contain approximately 5-
10µg von willebrand factor (VWF), 2-3mg fibrinogen and coagulation factors II, VII, 
IX, X, VIII (Bucur and Hillyer, 2001). FFP is rich with coagulation labile factor 
mainly factor V and factor VIII (Chng et al., 2003). FFP consist all coagulation 
factors rationalized the fact that it is useful to arrest bleeding due to coagulapathy.  
FFP should be given closed to the time of invasive procedure or surgery if 
correction of coagulopathy is required since the half life of some coagulation factor 
are short. FFP stored at -80°C can last for 36 months however once thawed, FFP 
shelf life reduced to 5 days when it is kept at 1-6°C and it is recommended to be used 
within 24 hours (Donegan et al., 2008).    
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1.4 Clinical indication of FFP 
The global trending of FFP transfusion has increased over the years despite the 
lack of scientific rationale and the potential harm (Liumbruno et al., 2009). 
Historically, during the World War II, besides treating trauma,  varieties of indication 
including sepsis (to neutralize toxin, not to treat coagulopathy), burn, nutritional 
deficiencies, nephrotic syndrome, sickle cell anaemia and acute lymphoblastic 
anaemia (ALL) (Puetz, 2013). Later , the administration of FFP is considered 
appropriate in patient with (Shander and Goodnough, 2007):- 
1. Prolonged PT or INR is greater than 1.5 in patient scheduled for invasive 
procedure and surgery 
2. During massive haemorrhage when INR exceeds 1.5 
3. Patient with thrombotic thrombocytopenic purpura (TTP) 
4. for treatment of inherited coagulopathies 
5. for which there are no specific concentrates available 
6. for anticoagulant-related bleeding 
It is then been confined to two main indications which are prophylactic to prevent 
bleeding in patient with coagulopathy before invasive procedure or surgery or as 
therapeutic to treat bleeding patients (Stanworth et al., 2007). Recommendation of 
FFP transfusion has been consistent in most guideline despite of having some 
variability in local guidelines. According to Guidelines for the rational use of blood 
and blood products (National Blood Centre, 2010), the recommended FFP 
transfusion includes: 
11 
 
1. For replacement of single factor deficiencies where specific or combined 
factor concentrate is not available. 
2. For immediate reversal of warfarin effect in the presence of potentially 
life-threatening bleeding when used in addition to vitamin K. 
3. For treatment of multiple coagulation deficiencies associated with acute 
disseminated intravascular coagulation. 
4. For the treatment of thrombotic thrombocytopaenic purpura. 
5. For the treatment of inherited deficiencies of coagulation inhibitors in 
patients undergoing high risk procedures where specific factor 
concentrate is unavailable. 
6. In the presence of bleeding and abnormal coagulation parameters 
following massive transfusion or cardiac bypass surgery or in patients 
with liver disease. 
The commonest inappropriate indication is to treat patients with abnormal 
coagulation tests who are not bleeding. An elevated PT/INR and APTT is presumed 
to be caused by coagulation factor deficiency and will cause increased risk of 
bleeding. FFP then should replace the coagulation factor deficiency and reduce risk 
of bleeding. While completely logical, this reason is based on assumptions which are 
incorrect (Holland and Brooks, 2006). 
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1.5 Administration of FFP 
FFP adequate dosage in most literature or guidelines is 10-15ml/kg or equivalent 
to 3-4 unit of FFP (Chaudhary et al., 2005). The typical volume of FFP derived from 
whole blood donation is about 200ml. American of Association of Blood Bank 
(AABB) guidance in the setting of massive transfusion is to use FFP if INR is greater 
than 1.5 (Roback et al., 2008). Factor level begins to drop below 30% as INR level 
prolong to more than 1.6. The administration of thawed FFP must be within 24 hours 
since some coagulation factor deteriorates over time such as factor VII that has half 
life of 4-6 hours (Yazer, 2010). 
1.6 The significant of abnormal coagulation parameters to guide FFP 
transfusion 
The principles of coagulation parameters must be understood to determine or 
guide for FFP transfusion. PT and APTT was first developed to investigate 
coagulation factor deficiencies, not to predict bleeding (Stanworth, 2007). PT and 
APTT are widely used global screening tests for blood coagulation. The end point for 
both tests are assessment of thrombin generation. They do not represent the 
comprehensive assessment of haemostasis. PT represent extrinsic pathway while 
APTT represent intrinsic pathways of the in vitro coagulation cascade (Bajaj and 
Joist, 1999). In vivo, however is more complex. The whole process of haemostasis is 
complicated by both pathways, platelet activation and vascular elements (Chee et al., 
2008). 
Both tests are usually affected by pre-analytical and analytical variables 
particularly the reagent use, technique and quality control of the laboratory. The 
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technique involved recording of clot formation time, mechanical, electromechanical 
or optical system. The normal reference range of APTT is 20-45 seconds while PT is 
10-14 seconds however this value varies for every hospital since it is generated from 
the establishment that is based on population value. Result for both tests may be 
outside of normal range because of certain factors such as biological variation of 
different individuals.  
Some conditions associated with both prolonged PT and APTT are severe liver 
disease, severe vitamin K deficiency, low-moderate intensity warfarin therapy 
(INR>2.5) and severe DIVC (Bajaj and Joist, 1999). PT is prolonged in more 
advanced liver disease because hepatic parenchymal cells are responsible to 
synthesized all clotting factors involved in extrinsic and common pathway. In DIVC, 
consumption of factor VIII, V and fibrinogen that interfere with fibrin 
polymerization lead to prolongation of PT (Bajaj and Joist, 1999). 
PT is commonly used to monitor certain anticoagulant therapy because it is 
sensitive to warfarin-induced decreases in the vitamin K dependent factor VII, X and 
prothrombin. The presences of human type tissue thromboplastin in PT reagent vary 
in sensitivities and thus may contribute to prolongation of PT too. Some reagent 
result in prolongation of coagulation time only when a relevant factor level drop to 
less than 30iu/dl. A controversial statement that PT is useful only for patient on 
Vitamin K antagonist and not useful for other condition such as liver disease is 
debateable (Tonna et al., 2007).  PT result has been greatly improved with the 
introduction of International normalized ratio (INR). The acceptable and common 
practice by many clinicians is INR≥1.5 to initiate FFP transfusion. 
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One study showed the relation between INR range and mean coagulation factor 
levels. For example, when INR is 1.3-1.9, mean coagulation factor levels for Factor 
II are 31-65%, Factor V is 70% and factor VII is 22-60%. They are considered 
sufficient to support haemostasis (Deitcher, 2002). 
Segal and Dzik (2005) performed and evidence based review of the ability of 
INR to predict bleeding from an invasive procedure taken from 25 studies (one from 
clinical trial and 24 from observational studies)(Segal and Dzik, 2005). It was found 
that bleeding rate of patients with or without abnormal coagulation was similar for 
some invasive procedure done and risk difference calculated showed little absolute 
difference. Hence, the author concluded that abnormal coagulation test does not 
predict bleeding in all patients.  
1.7 Adverse reactions of FFP transfusion 
In Hospital Selayang, a total of 6,881 and 6,497 units of FFP were transfused for 
2015 and 2016 respectively. Transfusion reaction cases reported in 2015 was 179 
while in 2016 was 147 cases. Out of 179 cases in 2015, 20% of the reaction is caused 
by FFP. The percentage is similar for 2016 (30/147 cases). The most common 
reactions are allergic and febrile non haemolytic reaction (unpublished data of 
Hospital Selayang). 
Besides, FFP transfusion also caused transfusion transmitted infection such as 
HIV, Hepatitis B, Hepatitis C and Syphilis. In Hospital Selayang, unpublished data 
from 2012 to 2016 shows 6 suspected seroconverted cases causes by FFP transfusion 
were investigated. Out of these 6 cases, 3 cases cannot be determine since patients 
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had passed away, 2 cases is still in ongoing investigation and 1 case is negative for 
the suspected infection which is HIV.  
Adverse transfusion reaction also includes actual error such as wrong blood 
administered to wrong patient. This reaction may result from acute haemolytic 
reaction to organ failure and worst, fatal complication that may caused death. In 
order to provide an intensive and effective haemovigilance programme, near misses 
must also be reported. According to Malaysian Patient Safety Goals: Guidelines on 
Implementation & Surveilance by Kementerian Kesihatan Malaysia in 2013, near 
misses means any error which if undetected could result in the determination of a 
wrong blood group or transfusion of an incorrect component but was recognized 
before transfusion took place (Patient Safety Council, 2013). 
Transfusion error and near misses has reduced in numbers over the past few 
years in Hospital Selayang (Table 7). The main problem that causes transfusion error 
and near misses is failure to identify patient in every significant step took place such 
as prior to blood taking activities and transfusion itself. Tremendous effort has been 
made by Blood Transfusion Unit and Hospital Transfusion Committee (HTC) to 
overcome the problem such as conducting Transfusion Safety Workshop every year, 
implementing transfusion checklist, continuous medical education (CME) for all 
housemen and counselling as well as extension of houseman period 
 
 
 
 
16 
 
Table 7: Summary of Transfusion Error and Near Misses from 2009 – 2016 in 
Hospital Selayang (unpublished data) 
Types of 
Error  
2009  2010  2011  2012  2013  2014  2015  2016 
NEAR MISSED  
Labelling & 
Sampling 
Error  
19 10  5  5  4  4 4 3 
Error in 
Blood Bank  
4  1  0  1  0  0  1 0 
INCIDENTS 
Discrepancy 
in Patient Info  
0 0  0  1  2  4 3 2 
Previous 
Error  
10 7  2  0  0  4  1 5 
TRANSFUSION ERROR  
Wrong blood 
given to 
wrong patient  
1  0  0  0  0  1  1 2 
Uncross 
matched 
blood given 
to patient  
0  1  0  0  0  0  0 0 
TOTAL 34 19 7 7 6 13 10 12 
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Other risks commonly associated with FFP transfusion include transfusion 
related lung injury (TRALI), transfusion associated circulatory overload (TACO), 
transfusion associated sepsis (TAS), TAGVHD, haemolytic transfusion reaction 
(HTR) and increased in mortality and morbidity. 
1.7.1 Transfusion related acute lung injury (TRALI) 
TRALI has emerged as the leading causes of transfusion related mortality 
reported by FDA in 2013. According to United Kingdom’s Serious Hazards of 
Transfusion (SHOT) hemovigilance data from 2003, TRALI risk was 6.9 times 
higher in FFP than in red cells. TRALI presented with acute hypoxemia and non-
cardiogenic pulmonary oedema during 6 hours of transfusion. Most patients recover 
within 3 days with respiratory support, however 5-25% cases are fatal. According to 
Rossi’s Principles of Transfusion Medicine, patient will experience respiratory 
distress such as shortness of breath, tightness in chest and dry cough. Patient often 
become hypoxic, hypotensive and tachycardia (Simon et al., 2016).  
Antibodies towards HLA antigen is the culprit in causing TRALI. Majority of 
cases (75-90%) were associated with HLA antibodies with 50% directed against 
HLA class II antigen (Win et al., 2008). About 10 to 25% of TRALI caused by 
antibodies to human neutrophil antigen (HNA). When leukocytes antibodies are 
transfused into a patient with cognate antigen, HLA class II and HNA antibodies 
(mainly HNA 3a) will indirectly activate neutrophil via monocyte activation and 
cytokine release. Neutrophils within the pulmonary microvasculature will then 
agglutinate and release enzymes, reactive oxygen species, and inflammatory 
mediators which injured the pulmonary endothelium (Pandey and Vyas, 2012). 
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The main strategy used to mitigate TRALI is to implement male-only plasma 
strategy since most donors implicated to TRALI were multiparous women and 
approximately 17% of female donor has leukocyte antibodies (Pandey and Vyas, 
2012). Risk of antibodies increases with more pregnancies. Many countries have 
implement this strategy such as UK, US, German, Canada and Netherlands. It is 
proven by many studies that by implementing this strategy, TRALI has reduced in 
number. One of the studies done is from American Red Cross that showed TRALI 
incidence become 1:250,000–317,000 (post mitigation) from 1:51,000–65,000 
plasma units issued pre-mitigation. In Netherland, a reduction of 33% of TRALI 
incidence after male only plasma strategy was implemented (Wiersum‐Osselton et 
al., 2011).   
 
1.7.2 Transfusion associated circulatory overload (TACO) 
TACO is similar to TRALI where it characterized as acute respiratory 
distress, hypoxia, pulmonary oedema temporarily associated with transfusion. 
However TACO is a hydrostatic not permeability oedema. There is no distinct 
clinical finding or test that can differentiate between TACO and TRALI but there are 
some signs and symptoms that can help such as chest x-ray, echocardiography and 
pulmonary artery occlusion pressure (Pandey and Vyas, 2012). TACO has received 
little attention in literature until recently in 2010, TACO was the second leading 
cause for mortality in the US as being reported in FDA/CBER: Fatalities reported to 
the FDA following blood collection and transfusion: Annual summary for fiscal year 
2010 (Food and Administration, 2011). TACO has been reported to be caused by a 
single red cells transfusion however, plasma transfusion is also a risk factor for 
TACO since large volume is usually needed in adult. TACO usually occurred in 
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cases of massive transfusion where large amount of blood and blood products are 
transfused to patient (Payandeh et al., 2013). 
1.7.3 Allergic/ anaphylactic transfusion reaction 
Allergic reaction is a common transfusion reaction due to various protein 
antigens present in plasma that can be a problem but rarely life threatening. 
Anaphylactic is characterized by systemic symptoms of bronchospasm, angioedema, 
and/or hypotension and estimated incidence ranges from 1:18,000 to 1:172,000 
transfusions (Pandey and Vyas, 2012). According to SHOT 2015 annual report, total 
number of reaction reported was 296, where 122 was because of allergic reaction 
(second highest after febrile-typed reaction = 142).  
1.7.4 Transfusion associated graft versus host disease (TAGVHD) 
TAGVHD is not typically associated with plasma transfusion since FFP is 
considered non-cellular. It is usually fatal and is caused by viable lymphocytes 
within a transfused product which engraft and proliferate within the transfusion 
recipient. Fortunately, TA-GVHD is rare and has never been reported with FFP 
(Pandey and Vyas, 2012). It has been estimated that TA-GVHD can occur with as 
few as 80,000 transfused lymphocytes, but a thawed plasma unit is unlikely to 
contain that number of viable lymphocytes (Sachs, 2010). 
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1.7.5 Transfusion associated sepsis (TAS) 
 
Blood is a good medium for bacteria growth and once contaminated it can 
cause death to the recipient. Plasma typically are not contaminated with bacteria 
since it is in frozen state. However the thawing process can easily exposed plasma to 
bacterial contamination. One study  in German reported that five cases of bacterial 
contamination in plasma were found from 1997 to 2007 (Keller‐Stanislawski et al., 
2009). According to Keller-Stanislawski et al, organism identified included species 
of Staphylococcus, Klebsiella, Propionibacterium, and Psuedomonas. Waterbaths 
used to thaw plasma are a potential source of contamination, and pseudomonas has 
been cultured from frozen products thawed in contaminated waterbaths (Pandey and 
Vyas, 2012). Care must be taken to properly clean and sterilize waterbaths regularly, 
and plasma should be transfused as soon as possible after thawing. 
 
1.7.6 Haemolytic transfusion reaction (HTR) 
 
Transfusion of an ABO incompatible plasma unit may cause a HTR, 
especially if the donor has high titer isohemmagglutinins. There have been multiple 
case reports of HTR after transfusion of a single unit (~200ml) of ABO-plasma 
incompatible platelets (i.e. Type O platelet to a Type A patient) (Pandey and Vyas, 
2012). To prevent HTR, transfusion service provides ABO compatible FFP to 
patients. If it is not available, FFP of a different ABO group that does not contain 
high titer anti-A or anti-B may be used (O'shaughnessy et al., 2004). 
 
 
